Innate Pharma (IPHYF) - Total Liabilities

Latest total liabilities as of June 2025: $87.79 Million USD

Based on the latest financial reports, Innate Pharma (IPHYF) has total liabilities worth $87.79 Million USD as of June 2025.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Innate Pharma - Total Liabilities Trend (2005–2024)

This chart illustrates how Innate Pharma's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Innate Pharma Competitors by Total Liabilities

The table below lists competitors of Innate Pharma ranked by their total liabilities.

Liability Composition Analysis (2005–2024)

This chart breaks down Innate Pharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Innate Pharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Innate Pharma (2005–2024)

The table below shows the annual total liabilities of Innate Pharma from 2005 to 2024.